High Quality Dabigatran Etexilate Mesylate 872728-81-9 for Sales for API

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Model NO.: Frazer-Dabigatran Etexilate Mesylate
• Appearance: White Powder
• CAS No: 872728-81-9
• Shelf Life: 2 Years
• Test Method: HPLC
• MOQ: 1kg
• Storage: Store Cool Dry Place
• Resource: Natural
• Quality Requirement: Strictly Quality Control
• Market: Worldwide
• Service: Welcome to Visit Us
• Delivery Time: 7-10days
• Standard: Enterprise Export
• Mf: C27h26n6o3
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2500kg/Month

Product Description

High Quality Dabigatran Etexilate Mesylate 872728-81-9 for Sales for API

Specification of Analysis

Item	Specification
Specific rotation	+39.5 to +41.5°
State of solution(transmittance)	Clear 98.0% min.
Chloride[cl]	0.020% max.
Ammonium [NH4]	0.02% max.
Sulfate[SO4]	0.020% max
Iron[Fe]	10ppm max.
Heavy metals [Pb]	10ppm max
Arsenic[As2O3]	1ppm max
Other amino acids	Chromatographically not detectable
Loss on drying	0.20% max.
Residue on ignition[sulfated]	0.10% max.
Assay	99.0% min

Product description

Dabigatran etexilate mesylate is a direct thrombin inhibitor used in clinical practice and a new type of oral anticoagulant. Its mechanism of action is to inhibit the formation of fibrin through reversible and strong competition to bind to the specific binding site of thrombin fibrin, thereby inhibiting the formation of thrombus.
Dabigatran etexilate mesylate is a raw material for the blood system; an anticoagulant drug; it can be used in patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism; Chemicalbook dabigatran etexilate is a new type of synthetic The direct thrombin inhibitor is a prodrug of dabigatran and is a non-peptide thrombin inhibitor.

Function:

Dabigatran is used to prevent strokes in those with atrial fibrillation not caused by heart valve issues, as well as deep vein thrombosis and pulmonary embolism in persons who have been treated for 5-10 days with parenteral anticoagulant (usually low molecular weight heparin), and to prevent deep vein thrombosis and pulmonary embolism in some circumstances.
It appears to be as effective as w'arfarin in preventing nonhemorrhagic strokes and embolic events in those with atrial fibrillation not due to valve problems.

Application:

The most commonly reported side effect of dabigatran is gastrointestinal upset. When compared to people anticoagulated with w'arfarin, patients taking dabigatran had fewer life-threatening bleeds, fewer minor and major bleeds, including intracranial bleeds, but the rate of gastrointestinal bleeding was significantly higher. Dabigatran capsules contain tartaric acid, which lowers the gastric pH and is required for adequate absorption. The lower pH has previously been associated with dyspepsia; some hypothesize that this plays a role in the increased risk of gastrointestinal bleeding.
A small but significantly increased risk of myocardial infarctions (heart attacks) has been noted when combining the safety outcome data from multiple trials.Reduced doses should be used in those with poor kidney function.